Oncology (Williston Park, N.Y.)

• 

  Publication Venue For

  • Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma..  37:176-183. 2023
  • The Evolving Role of Radiation Therapy in DLBCL: From Early-Stage to Refractory Disease..  36:718-727. 2022
  • Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs..  36:178-183. 2022
  • Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer..  35:654-660. 2021
  • The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform..  35:553-559. 2021
  • Prostate Cancer Focal Therapy Has Made Great Strides and the Future Remains Bright..  35:269. 2021
  • Are COVID-19 Delays a Basis for Concern? Can We Use This for Future Good?.  34:344-345. 2020
  • Managing Prostate Cancer Surgical Patients during the COVID-19 Pandemic: A Brief Report of the Duke Cancer Institute's Initial Experience..  34:156-162. 2020
  • CLINICAL TRIALS IN PROGRESS.  34:304-304. 2020
  • Counterpoint: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?.  33:235-242. 2019
  • Point: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?.  33:235-236. 2019
  • Counterpoint: Which Treatment Modality for Localized Prostate Cancer Yields Superior Quality of Life: Radiotherapy or Prostatectomy? Most Men With Clinically Important Localized Prostate Cancer Deserve First-Line Open or Robotic Radical Prostatectomy..  31:830-835. 2017
  • Most Men With Clinically Important Localized Prostate Cancer Deserve First-Line Open or Robotic Radical Prostatectomy.  31:830-+. 2017
  • How Can We Effectively Address the Medical and Psychological Concerns of Survivors of Pelvic Malignancies?.  31:286-294. 2017
  • Pubic Bone Osteomyelitis and Pubosymphyseal Urinary Fistula: A Poorly Recognized Complication in Prostate Cancer Survivors.  31:169-173. 2017
  • Pubic Bone Osteomyelitis and Pubosymphyseal Urinary Fistula: A Poorly Recognized Complication in Prostate Cancer Survivors.  31:169-173. 2017
  • Pubic Bone Osteomyelitis and Pubosymphyseal Urinary Fistula: A Poorly Recognized Complication in Prostate Cancer Survivors..  31:169-173. 2017
  • Multidisciplinary Management of Breast Cancer Brain Metastases..  30:923-933. 2016
  • Current Trends in the Management of Ductal Carcinoma In Situ.  30:823-831. 2016
  • Current Trends in the Management of Ductal Carcinoma In Situ.  30:823-831. 2016
  • Current Trends in the Management of Ductal Carcinoma In Situ..  30:823-831. 2016
  • Rising PSA Level in an Anxious Postprostatectomy Patient.  30. 2016
  • Rising PSA Level in an Anxious Postprostatectomy Patient.  30. 2016
  • Rising PSA Level in an Anxious Postprostatectomy Patient..  30:834-860. 2016
  • What's New in Genetic Testing for Cancer Susceptibility?.  30:787-799. 2016
  • What’s new in genetic testing for cancer susceptibility?.  30. 2016
  • Novel Androgen Receptor Signaling Inhibitors for Nonmetastatic Castration-Resistant Prostate Cancer: The Light at the End of the Tunnel-or an Oncoming Train?.  30:345-347. 2016
  • Vaccine Therapy, Oncolytic Viruses, and Gliomas..  30:211-218. 2016
  • What Should We Tell Patients About Physical Activity After a Prostate Cancer Diagnosis?.  29. 2015
  • What Should We Tell Patients About Physical Activity After a Prostate Cancer Diagnosis?.  29:680-694. 2015
  • Is radical prostatectomy appropriate for very-high-risk prostate cancer patients? No.  29. 2015
  • Subacute headache in a patient with metastatic gastric cancer.  29. 2015
  • Is radical prostatectomy appropriate for very-high-risk prostate cancer patients? No..  29:349-389. 2015
  • Subacute headache in a patient with metastatic gastric cancer.  29. 2015
  • Subacute headache in a patient with metastatic gastric cancer..  29:390-C3. 2015
  • ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury.  29:55-66. 2015
  • ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury..  29:55-66. 2015
  • Chemotherapy in soft-tissue sarcoma: where do we go from here?.  29. 2015
  • Chemotherapy in soft-tissue sarcoma: where do we go from here?.  29. 2015
  • Chemotherapy in soft-tissue sarcoma: where do we go from here?.  29:50-53. 2015
  • Improving outcomes in advanced DLBCL: systemic approaches and radiotherapy..  28:1074-1084. 2014
  • Low-risk and very-low-risk prostate cancer: is there a role for focal therapy in the era of active surveillance? Yes, the two approaches complement each other..  28:950-9C3. 2014
  • In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet.  28:883. 2014
  • In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet..  28:881-883. 2014
  • Thromboembolism and bleeding in bladder cancer..  28:847-854. 2014
  • Approaches for optimal drug development and clinical trial design for breast cancer brain metastasis..  28:579-585. 2014
  • It's time to have 'the talk': cost communication and patient-centered care..  28:479-480. 2014
  • Palliative radiotherapy for prostate cancer..  28:306-312. 2014
  • Curbing potential radiation-induced cancer risks in oncologic imaging: perspectives from the 'image gently' and 'image wisely' campaigns..  28:232-243. 2014
  • Active surveillance for African-American men with prostate cancer: of course! Pro..  28. 2014
  • Curbing potential radiation-induced cancer risks in oncologic imaging: perspectives from the 'image gently' and 'image wisely' campaigns..  28. 2014
  • It's time to have 'The talk': Cost communication and patient-centered care.  28:13. 2014
  • Palliative radiotherapy for prostate cancer..  28:306-312. 2014
  • Use of molecular biomarkers to inform adjuvant therapy for colon cancer..  27:746-754. 2013
  • Financial toxicity, Part II: how can we help with the burden of treatment-related costs?.  27:253-256. 2013
  • The state of prostate MRI in 2013..  27:262-270. 2013
  • The state of prostate MRI in 2013..  27:262-270. 2013
  • How can we optimize treatment of HER2-positive metastatic breast cancer?.  27. 2013
  • How can we optimize treatment of HER2-positive metastatic breast cancer?.  27:180-182. 2013
  • Financial toxicity, Part I: a new name for a growing problem..  27:80-149. 2013
  • Evolution of the concept of focal therapy for prostate cancer..  27. 2013
  • Evolution of the concept of focal therapy for prostate cancer..  27:64-70. 2013
  • Financial toxicity, Part I: a new name for a growing problem..  27. 2013
  • Financial toxicity, Part II: how can we help with the burden of treatment-related costs?.  27. 2013
  • Use of molecular biomarkers to inform adjuvant therapy for colon cancer.  27. 2013
  • Combined-modality therapy for early-stage Hodgkin lymphoma: maintaining high cure rates while minimizing risks..  26:1182-1193. 2012
  • Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority?.  26:741-743. 2012
  • Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority?.  26:741-743. 2012
  • Minimally invasive open retropubic prostatectomy: in experienced hands--still the gold standard..  26. 2012
  • Minimally invasive open retropubic prostatectomy: in experienced hands--still the gold standard..  26:610-615. 2012
  • Combined-modality therapy for early-stage Hodgkin lymphoma: Maintaining high cure rates while minimizing risks.  26. 2012
  • What to order from the prostate cancer treatment menu?.  26. 2012
  • The need for community-based palliative care for patients living with cancer.  25. 2011
  • Treatment of in-transit melanoma: an opportunity to discover critical knowledge..  25:1351-1355. 2011
  • Palliative care and oncology: integration leads to better care..  25:1275. 2011
  • Palliative care and oncology: integration leads to better care..  25:1271-1275. 2011
  • A role for hepatic metastasectomy in stage IV melanoma and breast cancer: reestablishing the surgical modality..  25:1158-1164. 2011
  • Role of radiation therapy in patients with resectable pancreatic cancer.  25:1-11. 2011
  • Liver transplantation for the treatment of hepatocellular carcinoma..  25:752-757. 2011
  • Role of radiation therapy in patients with resectable pancreatic cancer..  25:715-727. 2011
  • The impact of lobular histology on breast cancer treatment..  25:362-365. 2011
  • Putting Provenge in perspective..  25:255-258. 2011
  • Intraperitoneal chemotherapy for advanced epithelial ovarian cancer: Many questions, much promise&.  25. 2011
  • Lung cancer management in 2010..  25:64-73. 2011
  • Lung cancer management in 2010..  25:64-73. 2011
  • Radiation therapy in the management of diffuse large B-cell lymphoma: still relevant?.  24:1204-1212. 2010
  • Radiation therapy in the management of diffuse large B-cell lymphoma: still relevant?.  24:1204-1212. 2010
  • Hyperthermia and intravesical therapy: emerging one-two punch for bladder cancer?.  24:1161-1166. 2010
  • Hyperthermia as a treatment for bladder cancer..  24:1149-1155. 2010
  • Intensity-modulated radiation therapy for anal cancer: toxicity versus outcomes..  24. 2010
  • Intensity-modulated radiation therapy for anal cancer: toxicity versus outcomes..  24:815-828. 2010
  • Simultaneously detected bilateral testicular cancer of different histopathological origin--a challenging situation for the urologist..  24:757-760. 2010
  • Rare PTCLs: treatment lagging behind pathobiologic advances..  24:101-102. 2010
  • Intensity-modulated radiation therapy for anal cancer.  23. 2009
  • Intensity-modulated radiation therapy for anal cancer..  23:1082-1089. 2009
  • Response to antiangiogenesis therapy in a patient with advanced adult-type testicular granulosa cell tumor..  23:792-795. 2009
  • The road to romiplostim approval and beyond..  23. 2009
  • The road to romiplostim approval and beyond..  23:709-715. 2009
  • Novel approaches to 'borderline resectable' pancreatic tumors..  22:1529-1530. 2008
  • Multidisciplinary Management of Resectable Rectal Cancer New Developments and Controversies The Minsky/Guillem Article Reviewed.  22:1441-+. 2008
  • Thirty years of rectal cancer research: a brief history..  22:1441-1444. 2008
  • An odd but synergistic couple: Immunotherapy combined with radiotherapy.  22:1075-1080. 2008
  • From whole-gland to targeted cryoablation for the treatment of unilateral or focal prostate cancer..  22:900-906. 2008
  • Postoperative radiation therapy for lung cancer: where do we stand?.  22:301-310. 2008
  • Radiation-induced lung injury. Assessment, management, and prevention..  22:37-47. 2008
  • 'Unresectable' pancreatic cancer: Conceptual challenges.  21:1571-1572. 2007
  • Rising PSA in nonmetastatic prostate cancer..  21:1436-1445. 2007
  • Monitoring changes in the microenvironment during targeted therapies.  21:1354-1370. 2007
  • Targeted therapy in rectal cancer..  21:1055-1065. 2007
  • Monoclonal antibodies to EGFR: What does the future hold?.  21:976-977. 2007
  • Monoclonal antibodies to EGFR: What does the future hold? The Burtness article reviewed.  21:976-977. 2007
  • The moving target of cancer care costs.  21:862+866. 2007
  • Chemotherapy dose intensity and quality cancer care..  20:16-25. 2006
  • The Extermann article reviewed.  20. 2006
  • The Merrick/Wallner/Butler et al article reviewed.  20:524-525. 2006
  • The Witherby/Muss article reviewed.  20:1017-1018. 2006
  • Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer - The Morris/Carey article reviewed.  20:1775-1776. 2006
  • Stage III lung cancer: two or three modalities? The continued role of thoracic radiotherapy..  20:1210-1219. 2006
  • Managing early-stage breast cancer in your older patients.  20:1017-1018. 2006
  • Benefits of early intervention with erythropoiesis- stimulating proteins in chemotherapy-induced anemia..  20:16-20. 2006
  • Erythropoiesis-stimulating protein support and survival..  20:39-43. 2006
  • Radiation therapy in the treatment of cholangiocarcinoma..  20:873-884. 2006
  • Colony-stimulating factor use in the context of refined risk and benefit assessments..  20:9-10. 2006
  • Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia..  20:22-28. 2006
  • Radiation therapy for resectable colon cancer. Is there a role in the modern chemotherapy era?.  20:179-187. 2006
  • Permanent prostate brachytherapy: Is supplemental external-beam radiation therapy necessary? The Merrick/Wallner/Butler et al Article reviewed.  20:524-525. 2006
  • The Chadha/Kuvshinoff/Javle article reviewed.  19:1231-1232. 2005
  • The Pisters/Wolff/Crane et al article reviewed.  19. 2005
  • Neoadjuvant therapy for gastric cancer - The Chadha/Kuvshinoff/Javle article reviewed.  19:1231-1232. 2005
  • Antifungal resistance: the clinical front..  18:15-22. 2004
  • Management of invasive mycoses in hematology patients: current approaches..  18:5-14. 2004
  • Prostatectomy vs brachytherapy for localized prostate cancer..  18:1582-1585. 2004
  • Recent advances in the treatment of pediatric brain tumors..  18:1649-1661. 2004
  • Use of newer antifungal therapies in clinical practice: what do the data tell us?.  18:15-23. 2004
  • Comparing radical prostatectomy and brachytherapy for localized prostate cancer..  18:1289-1302. 2004
  • Monoclonal antibodies: the foundation of therapy for colorectal cancer in the 21st century?.  18:736-741. 2004
  • The Damjanov/Meropol article reviewed.  18:488-493. 2004
  • Update on combined-modality treatment options for pancreatic cancer..  17:29-36. 2003
  • Introduction. Neutropenia risk models in oncology..  17:5-7. 2003
  • Risk assessment in oncology clinical practice. From risk factors to risk models..  17:8-13. 2003
  • Treatment of complications after breast-conservation therapy..  17:1118-1128. 2003
  • Irinotecan: promising activity in the treatment of malignant glioma..  17:9-14. 2003
  • Physical function in men and women with cancer. Effects of anemia and conditioning..  16:109-115. 2002
  • Prostate-specific antigen as a marker of disease activity in prostate cancer..  16:1218-1224. 2002
  • Recombinant human erythropoietin in cancer-related anemia. Review of clinical evidence..  16:41-53. 2002
  • Prostate-specific antigen as a marker of disease activity in prostate cancer..  16:1024-1042. 2002
  • The sentinel node in colorectal carcinoma. Mapping technique, pathologic assessment, and clinical relevance..  16:567-580. 2002
  • The role of amifostine as a radioprotector..  15:1349-1354. 2001
  • Systemic therapy for older women with breast cancer..  15:280-291. 2001
  • The Lichtman/Skirvin article reviewed.  14:1760-1763. 2000
  • Current perspectives on locally advanced pancreatic cancer..  14:1535-1545. 2000
  • NCCN Practice Guidelines for Acute Myelogenous Leukemia..  14:53-61. 2000
  • NCCN Practice Guidelines for Chronic Myelogenous Leukemia..  14:229-240. 2000
  • NCCN Practice Guidelines for acute myelogenous leukemia.  14:53-61. 2000
  • NCCN Practice Guidelines for chronic myelogenous leukemia.  14:229-240. 2000
  • Rising PSA after local therapy failure: immediate vs deferred treatment..  13:985-993. 1999
  • QOL and outcomes research in prostate cancer patients with low socioeconomic status..  13:823-832. 1999
  • Autocrine Growth Factors and Neuroendocrine Markers in the Development of Small-Cell Lung Cancer.  12:11-14. 1998
  • Preclinical and clinical results with irinotecan: Extending principles learned in model systems to clinical trials design.  12:84-93. 1998
  • Extending principles learned in model systems to clinical trials design..  12:84-93. 1998
  • Irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer..  12:79-83. 1998
  • Preclinical and clinical results with irinotecan - Extending principles learned in model systems to clinical trials design.  12:84-93. 1998
  • Contemporary hormonal management of advanced prostate cancer..  12:499-505. 1998
  • Molecular genetics of hereditary ovarian cancer - The Boyd article reviewed.  12:410-+. 1998
  • Autocrine growth factors and neuroendocrine markers in the development of small-cell lung cancer..  12:11-14. 1998
  • NCCN practice guidelines for occult primary tumors.  12:226-309. 1998
  • The Michael/Moore Article Reviewed.  11:1622-1625. 1997
  • The Wilt et al Article Reviewed.  11:1140-1143. 1997
  • Vinorelbine and Carboplatin in the Treatment of Advanced Non-Small-Cell Lung Cancer.  11:44-48. 1997
  • NCCN practice guidelines for pancreatic cancer..  11:41-55. 1997
  • Docetaxel/vinorelbine combination therapy in non-small-cell lung cancer.  11:35-40. 1997
  • Prostate cancer surgical practice guidelines. Society of Surgical Oncology practice guidelines..  11:907-912. 1997
  • Prognostic factors in low-stage nonseminomatous testicular cancer..  10:1359-1374. 1996
  • State of the art in umbilical cord transplantation..  10:1086-1091. 1996
  • A cost analysis of hematopoietic colony-stimulating factors..  9:85-91. 1995
  • Current status of endocrine therapy for metastatic breast cancer..  9:877-890. 1995
  • Current management of acute lymphoblastic leukemia in adults..  9:433-442. 1995
  • Malignant gliomas in older adults with poor prognostic signs. Getting nowhere, and taking a long time to do it..  9:229-234. 1995
  • Quality of life after bone marrow transplantation..  8:19-27. 1994
  • Cancer epidemiology in the Far East--contrast with the United States..  7:99-110. 1993
  • New therapeutic options in the management of childhood brain tumors..  6:27-36. 1992
  • Current and future treatment of HIV infection..  4:19-29. 1990
  • Indications for adjuvant radiotherapy in extrapelvic colonic carcinoma..  3:25-31. 1989
  • The urology perspective on expanding androgen-targeted treatments for men with castration-resistant prostate cancer..  28:702-722. 2014
  • Active surveillance for African-American men with prostate cancer: of course! Pro..  28:82-85. 2014
  • What to Order From the Prostate Cancer Treatment Menu? THE CRAWFORD/FLAIG ARTICLE REVIEWED.  26:84-+. 2012
  • What to order from the prostate cancer treatment menu?.  26:84-88. 2012
  • Putting Provenge in perspective..  25:255-258. 2011
  • The Eisenberger/Sinibaldi article reviewed.  20:863. 2006
  • The role of cytotoxic chemotherapy in prostate cancer - A critical reevaluation 20 years later - The Eisenberger/Sinibaldi article reviewed.  20:863-863. 2006
  • Treating the troops a model for battling health-care disparities.  20:318-318. 2006
  • Surgical management of hepatic breast cancer metastases: Commentary.  19:1587-1596. 2005
  • The Cooperberg/Park/Carroll article reviewed.  18:1248-1256. 2004
  • The D'Amico article reviewed: The CPDR/CaPSURE recurrence equation.  15:1060-1062. 2001
  • The Wexner/Hwang article reviewed.  14:1143-1144. 2000
  • The Powell Article Reviewed.  11:611-618. 1997
  • The current clinical value of the DCIS Score. 2014
  • NCCN practice guidelines for occult primary tumors. National Comprehensive Cancer Network. 1998
  • NCCN practice guidelines for the myelodysplastic syndromes. National Comprehensive Cancer Network. 1998